ImmunityBio price target raised to $15 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on ImmunityBio (IBRX) to $15 from $10 and keeps a Buy rating on the shares. The recent European Union approval expands Anktiva’s footprint to 33 countries, “removing a major regulatory overhang and opening a meaningful incremental commercial opportunity,” the analyst tells investors in a research note.